ArticlePloS one2018
Metabolomic profiling for the identification of potential biomarkers involved in a laboratory azole resistance in Candida albicans.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 31 citations in OpenAlex.
- Network Pharmacology-Guided Identification ofInternational journal of molecular sciences · 2026Article
- Genome-scale metabolic modelling of the priority fungal pathogenmicroLife · 2026Article
- Omics and Multiomics-Based Diagnostics for Invasive Candidiasis: Toward Precision Medicine.Molecular & cellular proteomics : MCP · 2025Review
- Extracellular Vesicles From Fungal Infection in Humans: A Key Player in Immunological Responses.Journal of extracellular biology · 2025Article
- Stepping out of the dark: how metabolomics shed light on fungal biology.FEMS microbiology reviews · 2025Review
- Fungal Metabolomics: A Comprehensive Approach to Understanding Pathogenesis in Humans and Identifying Potential Therapeutics.Journal of fungi (Basel, Switzerland) · 2025Review
- Metabolic Patterns of Fluconazole Resistant and SusceptibleJournal of fungi (Basel, Switzerland) · 2024Article
- Article
- Mass Spectrometry Analysis Reveals Lipids Induced by Oxidative Stress inMicroorganisms · 2023Article
- The Metabolism of Susceptibility: Clearing the FoG Between Tolerance and Resistance inCurrent clinical microbiology reports · 2023Article
- Biomarkers of caspofungin resistance inVirulence · 2022Article
- Metabolic Plasticity ofJournal of fungi (Basel, Switzerland) · 2022Article
- Diagnosis and Treatment of Invasive Candidiasis.Antibiotics (Basel, Switzerland) · 2022Review
- A Proteomic Landscape of Candida albicans in the Stepwise Evolution to Fluconazole Resistance.Antimicrobial agents and chemotherapy · 2022Article
- Impact of the Peptide WMR-K on Dual-Species BiofilmPathogens (Basel, Switzerland) · 2021Article
- Article
- Metabolic profiling of Candida clinical isolates of different species and infection sources.Scientific reports · 2020Article
- Review
- Mechanism of Candida pathogenesis: revisiting the vital drivers.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020Review
- Catch the wave: Metabolomic analyses in human pathogenic fungi.PLoS pathogens · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candida albicans, one of the most common fungal pathogens, is responsible for several yeast infections in human hosts, being resistant to classically used antifungal drugs, such as azole drugs. Multifactorial and multistep alterations are involved in the azole resistance in Candida albicans. In this study, a FCZ-resistant C. albicans strain was obtained by serial cultures of a FCZ-susceptible C. albicans strain in incrementally increasing concentrations of FCZ. We performed an integrated profile of different classes of molecules related to azole resistance in C. albicans by combining several mass-spectrometry based methodologies. The comparative metabolomic study was performed with the sensitive and resistant strains of C.albicans to identify metabolites altered during the development of resistance to fluconazole, while the intervention strains and non-intervention strains of C.albicans to identify metabolites altered involved in cross-resistant to azole drugs. Our analysis of the different metabolites identified molecules mainly involved in metabolic processes such as amino acid metabolism, tricarboxylic acid cycle and phospholipid metabolism. We also compared the phospholipid composition of each group, revealing that the relative content of phospholipids significantly changed during the development of resistance to azole drugs. According with these results, we hypothesized that the metabolism shift might contribute to azole drugs resistance in C.albicans from multifactorial alterations. Our result paves the way to understand processes underlying the resistance to azole drugs in C. albicans, providing the basis for developing new antifungal drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.